Study Supported by $2.6
Million FDA Orphan Products Development Grant
PRINCETON, N.J., Jan. 14,
2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX)
(Soligenix or the Company), a late-stage biopharmaceutical company
focused on developing and commercializing products to treat rare
diseases where there is an unmet medical need, announced an interim
update on the open-label, investigator-initiated study (IIS)
evaluating extended HyBryte™ (synthetic hypericin) treatment for up
to 12 months in patients with early-stage cutaneous T-cell lymphoma
(CTCL). The trial is sponsored by Ellen
Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice
Chair of Clinical Operations, Dermatology Department, and Professor
of Dermatology at the Hospital of the University of Pennsylvania who was a leading
enroller in the Phase 3 FLASH (Fluorescent Light Activated
Synthetic Hypericin) study for the treatment of
early-stage CTCL. To date, nine patients have been enrolled and
treated with HyBryte™ over a time period of up to 54 weeks.
Patients have responded positively to HyBryte™ therapy, with over
70% (5 of the 6 subjects who have completed at least 18 weeks of
therapy) already achieving "Treatment Success". Treatment Success
is predefined in the study's protocol as a greater than or equal to
50% improvement in the cumulative mCAILS (modified Composite
Assessment of Index Lesion Severity) score compared to Baseline. Of
the five Treatment Successes, three were achieved within the first
12 weeks of treatment, with two patients achieving a "complete
response" by 18 weeks. Of the remaining patients, two have recently
started the study and two had to drop from the study for logistical
reasons (e.g., need to care for an elderly parent), with one
showing a substantial improvement (>30%) by their Week 18 visit.
In addition, HyBryte™ appears to be safe and well tolerated in all
patients.
"The complete response rate, consistent treatment response and
safety profile across multiple clinical studies to date with
HyBryte™ has been exciting to see," noted Dr. Kim, Principal
Investigator of the IIS and Lead Investigator of the FLASH2 study.
"In the first Phase 3 FLASH study, HyBryte™ was shown to be
efficacious with a benign safety profile compared to the current
therapies of steroids, chemotherapeutics and ultraviolet light in
this chronic orphan disease. With limited treatment options,
especially in the early stages of their disease, CTCL patients are
often searching for alternative treatments. In our U.S. Food and
Drug Administration (FDA)-funded study, initial results evaluating
the expanded use of HyBryte™ in a "real world" treatment setting
remain very promising, further supporting and extending results
from the previous positive Phase 2 and 3 clinical trials. We look
forward to continuing to work with the FDA to complete this study
while we participate in the confirmatory Phase 3 placebo-controlled
FLASH2 study."
"We are pleased with these recent study results and that the FDA
is continuing to financially support the HyBryte™ program, giving
patients an opportunity to access the therapy in an open-label
setting," stated Christopher J.
Schaber, PhD, President and Chief Executive Officer of
Soligenix. "CTCL is an incredibly difficult to treat orphan disease
and remains an area of unmet medical need with a very limited
number of safe and effective treatment options. Following the
initial Phase 3 FLASH study, which demonstrated the safety and
efficacy of shorter courses of HyBryte™ therapy, we are pleased to
see that continuing treatment for longer time periods is resulting
in the anticipated improved outcomes for patients. As the body of
compelling data continues to grow in support of this novel therapy,
we look forward to continuing to work with Dr. Kim on this
important study as well as advancing enrollment in the 80-patient
confirmatory Phase 3 FLASH2 replication study. We will plan to
provide additional updates on the IIS as data becomes
available."
The clinical study RW-HPN-MF-01, "Assessment of Treatment with
Visible Light Activated Synthetic Hypericin Ointment in Mycosis
Fungoides Patients" is designed as an open-label, multicenter
clinical trial enrolling approximately 20 patients in the U.S.
Patients have the potential to be treated for up to 12 months with
twice a week dosing (visible light activation following ointment
application by 24 ± 6 hours). The study also allows for potential
transition to a "real-world" setting with home-use. The primary
endpoint for the study is evaluating the number of treatment
successes defined as ≥50% reduction in the cumulative mCAILS score
from Baseline to end of the treatment.
About HyBryte™
HyBryte™ (research name SGX301) is a novel, first-in-class,
photodynamic therapy utilizing safe, visible light for activation.
The active ingredient in HyBryte™ is synthetic hypericin, a potent
photosensitizer that is topically applied to skin lesions that is
taken up by the malignant T-cells, and then activated by safe,
visible light approximately 24 hours later. The use of visible
light in the red-yellow spectrum has the advantage of penetrating
more deeply into the skin (much more so than ultraviolet light) and
therefore potentially treating deeper skin disease and thicker
plaques and lesions. This treatment approach avoids the risk of
secondary malignancies (including melanoma) inherent with the
frequently employed DNA-damaging drugs and other phototherapy that
are dependent on ultraviolet exposure. Combined with
photoactivation, hypericin has demonstrated significant
anti-proliferative effects on activated normal human lymphoid cells
and inhibited growth of malignant T-cells isolated from CTCL
patients. In a published Phase 2 clinical study in CTCL, patients
experienced a statistically significant (p=0.04) improvement with
topical hypericin treatment whereas the placebo was ineffective.
HyBryte™ has received orphan drug and fast track designations from
the FDA, as well as orphan designation from the European Medicines
Agency (EMA).
The published Phase 3 FLASH trial enrolled a total of 169
patients (166 evaluable) with Stage IA, IB or IIA CTCL. The trial
consisted of three treatment cycles. Treatments were administered
twice weekly for the first 6 weeks and treatment response was
determined at the end of the 8th week of each cycle. In the first
double-blind treatment cycle (Cycle 1), 116 patients received
HyBryte™ treatment (0.25% synthetic hypericin) and 50 received
placebo treatment of their index lesions. A total of 16% of the
patients receiving HyBryte™ achieved at least a 50% reduction in
their lesions (graded using a standard measurement of dermatologic
lesions, the CAILS score) compared to only 4% of patients in the
placebo group at 8 weeks (p=0.04) during the first treatment cycle
(primary endpoint). HyBryte™ treatment in this cycle was safe and
well tolerated.
In the second open-label treatment cycle (Cycle 2), all patients
received HyBryte™ treatment of their index lesions. Evaluation of
155 patients in this cycle (110 receiving 12 weeks of HyBryte™
treatment and 45 receiving 6 weeks of placebo treatment followed by
6 weeks of HyBryte™ treatment), demonstrated that the response rate
among the 12-week treatment group was 40% (p<0.0001 vs the
placebo treatment rate in Cycle 1). Comparison of the 12-week and
6-week treatment responses also revealed a statistically
significant improvement (p<0.0001) between the two timepoints,
indicating that continued treatment results in better outcomes.
HyBryte™ continued to be safe and well tolerated. Additional
analyses also indicated that HyBryte™ is equally effective in
treating both plaque (response 42%, p<0.0001 relative to placebo
treatment in Cycle 1) and patch (response 37%, p=0.0009 relative to
placebo treatment in Cycle 1) lesions of CTCL, a particularly
relevant finding given the historical difficulty in treating plaque
lesions in particular.
The third (optional) treatment cycle (Cycle 3) was focused on
safety and all patients could elect to receive HyBryte™ treatment
of all their lesions. Of note, 66% of patients elected to continue
with this optional compassionate use / safety cycle of the study.
Of the subset of patients that received HyBryte™ throughout all 3
cycles of treatment, 49% of them demonstrated a positive treatment
response (p<0.0001 vs patients receiving placebo in Cycle 1).
Moreover, in a subset of patients evaluated in this cycle, it was
demonstrated that HyBryte™ is not systemically available,
consistent with the general safety of this topical product observed
to date. At the end of Cycle 3, HyBryte™ continued to be well
tolerated despite extended and increased use of the product to
treat multiple lesions.
Overall safety of HyBryte™ is a critical attribute of this
treatment and was monitored throughout the three treatment cycles
(Cycles 1, 2 and 3) and the 6-month follow-up period. HyBryte's™
mechanism of action is not associated with DNA damage, making it a
safer alternative than currently available therapies, all of which
are associated with significant, and sometimes fatal, side effects.
Predominantly these include the risk of melanoma and other
malignancies, as well as the risk of significant skin damage and
premature skin aging. Currently available treatments are only
approved in the context of previous treatment failure with other
modalities and there is no approved front-line therapy available.
Within this landscape, treatment of CTCL is strongly motivated by
the safety risk of each product. HyBryte™ potentially represents
the safest available efficacious treatment for CTCL. With very
limited systemic absorption, a compound that is not mutagenic and a
light source that is not carcinogenic, there is no evidence to date
of any potential safety issues.
Following the first Phase 3 study of HyBryte™ for the treatment
of CTCL, the FDA and the EMA indicated that they would require a
second successful Phase 3 trial to support marketing approval. With
agreement from the EMA on the key design components, the second,
confirmatory study, called FLASH2, is expected to be initiated
before the end of 2024. This study is a randomized, double-blind,
placebo-controlled, multicenter study that will enroll
approximately 80 subjects with early-stage CTCL. The
FLASH2 study replicates the double-blind, placebo-controlled
design used in the first successful Phase 3 FLASH study that
consisted of three 6-week treatment cycles (18 weeks total), with
the primary efficacy assessment occurring at the end of the initial
6-week double-blind, placebo-controlled treatment cycle (Cycle 1).
However, this second study extends the double-blind,
placebo-controlled assessment to 18 weeks of continuous
treatment (no "between-Cycle" treatment breaks) with the primary
endpoint assessment occurring at the end of the 18-week timepoint.
In the first Phase 3 study, a treatment response of 49%
(p<0.0001 vs patients receiving placebo in Cycle 1) was observed
in patients completing 18 weeks (3 cycles) of therapy. In this
second study, all important clinical study design components remain
the same as in the first FLASH study, including the primary
endpoint and key inclusion-exclusion criteria. The extended
treatment for a continuous 18 weeks in a single cycle is expected
to statistically demonstrate HyBryte's™ increased effect over a
more prolonged, "real world" treatment course. Given the extensive
engagement with the CTCL community, the esteemed Medical Advisory
Board and the previous trial experience with this disease,
accelerated enrollment in support of this study is anticipated,
including the potential to enroll previously identified and treated
HyBryte™ patients from the FLASH study. Discussions with the FDA on
an appropriate study design remain ongoing. While collaborative,
the agency has expressed a preference for a longer duration
comparative study over a placebo-controlled trial. Given the
shorter time to potential commercial revenue and the similar trial
design to the first FLASH study afforded by the EMA accepted
protocol, this study is being initiated. At the same time,
discussions with the FDA will continue on potential modifications
to the development path to adequately address their feedback.
Additional supportive studies have demonstrated the utility of
longer treatment times (Study RW-HPN-MF-01, see above), the lack of
significant systemic exposure to hypericin after topical
application (Study HPN-CTCL-02) and its relative efficacy and
tolerability compared to Valchlor® (Study
HPN-CTCL-04).
In addition, the FDA awarded an Orphan Products Development
grant to support the investigator-initiated study evaluation of
HyBryte™ for expanded treatment in patients with early-stage CTCL,
including in the home use setting. The grant, totaling $2.6 million over 4 years, was awarded to the
University of Pennsylvania that was a
leading enroller in the Phase 3 FLASH study.
About Cutaneous T-Cell Lymphoma (CTCL)
CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of
cancer of the white blood cells that are an integral part of the
immune system. Unlike most NHLs which generally involve B-cell
lymphocytes (involved in producing antibodies), CTCL is caused by
an expansion of malignant T-cell lymphocytes (involved in
cell-mediated immunity) normally programmed to migrate to the skin.
These malignant cells migrate to the skin where they form various
lesions, typically beginning as patches and may progress to raised
plaques and tumors. Mortality is related to the stage of CTCL, with
median survival generally ranging from about 12 years in the early
stages to only 2.5 years when the disease has advanced. There is
currently no cure for CTCL. Typically, CTCL lesions are treated and
regress but usually return either in the same part of the body or
in new areas.
CTCL constitutes a rare group of NHLs, occurring in about 4% of
the more than 1.7 million individuals living with the disease in
the U.S. and Europe (European
Union and United Kingdom). It is
estimated, based upon review of historic published studies and
reports and an interpolation of data on the incidence of CTCL that
it affects approximately 31,000 individuals in the U.S. (based on
SEER data, with approximately 3,200 new cases seen annually) and
approximately 38,000 individuals in Europe (based on ECIS prevalence estimates,
with approximately 3,800 new cases annually).
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on
developing and commercializing products to treat rare diseases
where there is an unmet medical need. Our Specialized
BioTherapeutics business segment is developing and moving toward
potential commercialization of HyBryte™ (SGX301 or synthetic
hypericin sodium) as a novel photodynamic therapy utilizing safe
visible light for the treatment of cutaneous T-cell lymphoma
(CTCL). With successful completion of the second Phase 3 study,
regulatory approvals will be sought to support potential
commercialization worldwide. Development programs in this business
segment also include expansion of synthetic hypericin (SGX302) into
psoriasis, our first-in-class innate defense regulator (IDR)
technology, dusquetide (SGX942) for the treatment of inflammatory
diseases, including oral mucositis in head and neck cancer, and
(SGX945) in Behçet's Disease.
Our Public Health Solutions business segment includes
development programs for RiVax®, our ricin toxin vaccine candidate,
as well as our vaccine programs targeting filoviruses (such as
Marburg and Ebola) and CiVax™, our vaccine candidate for the
prevention of COVID-19 (caused by SARS-CoV-2). The development of
our vaccine programs incorporates the use of our proprietary heat
stabilization platform technology, known as ThermoVax®. To date,
this business segment has been supported with government grant and
contract funding from the National Institute of Allergy and
Infectious Diseases (NIAID), the Defense Threat Reduction Agency
(DTRA) and the Biomedical Advanced Research and Development
Authority (BARDA).
For further information regarding Soligenix, Inc., please visit
the Company's website at https://www.soligenix.com and
follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that
reflect Soligenix's current expectations about its future results,
performance, prospects and opportunities, including but not limited
to, potential market sizes, patient populations, clinical trial
enrollment, the expected timing for closing the offering described
herein and the intended use of proceeds therefrom. Statements that
are not historical facts, such as "anticipates," "estimates,"
"believes," "hopes," "intends," "plans," "expects," "goal," "may,"
"suggest," "will," "potential," or similar expressions, are
forward-looking statements. These statements are subject to a
number of risks, uncertainties and other factors that could cause
actual events or results in future periods to differ materially
from what is expressed in, or implied by, these statements, and
include the expected amount and use of proceeds from the offering
and the expected closing date of the offering. Soligenix cannot
assure you that it will be able to successfully develop, achieve
regulatory approval for or commercialize products based on its
technologies, particularly in light of the significant uncertainty
inherent in developing therapeutics and vaccines against bioterror
threats, conducting preclinical and clinical trials of therapeutics
and vaccines, obtaining regulatory approvals and manufacturing
therapeutics and vaccines, that product development and
commercialization efforts will not be reduced or discontinued due
to difficulties or delays in clinical trials or due to lack of
progress or positive results from research and development efforts,
that it will be able to successfully obtain any further funding to
support product development and commercialization efforts,
including grants and awards, maintain its existing grants which are
subject to performance requirements, enter into any biodefense
procurement contracts with the U.S. Government or other countries,
that it will be able to compete with larger and better financed
competitors in the biotechnology industry, that changes in health
care practice, third party reimbursement limitations and Federal
and/or state health care reform initiatives will not negatively
affect its business, or that the U.S. Congress may not pass any
legislation that would provide additional funding for the Project
BioShield program. In addition, there can be no assurance as to the
timing or success of any of its clinical/preclinical trials.
Despite the statistically significant result achieved in the first
HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of
cutaneous T-cell lymphoma, there can be no assurance that the
second HyBryte™ (SGX301) Phase 3 clinical trial will be successful
or that a marketing authorization from the FDA or EMA will be
granted. Additionally, although the EMA has agreed to the key
design components of the second HyBryte™ (SGX301) Phase 3 clinical
trial, no assurance can be given that the Company will be able to
modify the development path to adequately address the FDA's
concerns or that the FDA will not require a longer duration
comparative study. Notwithstanding the result in the first HyBryte™
(SGX301) Phase 3 clinical trial for the treatment of cutaneous
T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the
treatment of psoriasis, there can be no assurance as to the timing
or success of the clinical trials of SGX302 for the treatment of
psoriasis. Additionally, despite the biologic activity observed in
aphthous ulcers induced by chemotherapy and radiation, there can be
no assurance as to the timing or success of the clinical trials of
SGX945 for the treatment of Behçet's Disease. Further, there can be
no assurance that RiVax® will qualify for a biodefense
Priority Review Voucher (PRV) or that the prior sales of PRVs will
be indicative of any potential sales price for a PRV for
RiVax®. Also, no assurance can be provided that the
Company will receive or continue to receive non-dilutive government
funding from grants and contracts that have been or may be awarded
or for which the Company will apply in the future. These and other
risk factors are described from time to time in filings with the
Securities and Exchange Commission (the "SEC"), including, but not
limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless
required by law, Soligenix assumes no obligation to update or
revise any forward-looking statements as a result of new
information or future events.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hybryte-expanded-treatment-continues-to-demonstrate-positive-outcomes-in-early-stage-cutaneous-t-cell-lymphoma-302350395.html
SOURCE SOLIGENIX, INC.